- Home
- MCRB vs FBRX Comparison
MCRB vs FBRX Comparison
Compare MCRB & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- FBRX
- Stock Information
- Founded
- MCRB 2010
- FBRX N/A
- Country
- MCRB United States
- FBRX United States
- Employees
- MCRB N/A
- FBRX N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- MCRB Health Care
- FBRX Health Care
- Exchange
- MCRB Nasdaq
- FBRX Nasdaq
- Market Cap
- MCRB 144.6M
- FBRX 154.5M
- IPO Year
- MCRB 2015
- FBRX N/A
- Fundamental
- Price
- MCRB $20.76
- FBRX $14.06
- Analyst Decision
- MCRB Hold
- FBRX Strong Buy
- Analyst Count
- MCRB 4
- FBRX 3
- Target Price
- MCRB $14.33
- FBRX $68.00
- AVG Volume (30 Days)
- MCRB 227.9K
- FBRX 104.7K
- Earning Date
- MCRB 11-12-2025
- FBRX 11-13-2025
- Dividend Yield
- MCRB N/A
- FBRX N/A
- EPS Growth
- MCRB N/A
- FBRX N/A
- EPS
- MCRB 10.22
- FBRX N/A
- Revenue
- MCRB N/A
- FBRX N/A
- Revenue This Year
- MCRB N/A
- FBRX N/A
- Revenue Next Year
- MCRB N/A
- FBRX N/A
- P/E Ratio
- MCRB $2.05
- FBRX N/A
- Revenue Growth
- MCRB N/A
- FBRX N/A
- 52 Week Low
- MCRB $6.53
- FBRX $4.11
- 52 Week High
- MCRB $24.67
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- MCRB 59.57
- FBRX 53.68
- Support Level
- MCRB $19.14
- FBRX $13.19
- Resistance Level
- MCRB $21.97
- FBRX $15.49
- Average True Range (ATR)
- MCRB 1.52
- FBRX 1.51
- MACD
- MCRB 0.22
- FBRX -0.04
- Stochastic Oscillator
- MCRB 78.90
- FBRX 44.54
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).